^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NY-ESO-1 combined with MPLA vaccine

i
Other names: NY-ESO-1 combined with MPLA vaccine
Associations
Trials
Company:
National Institute of Science and Technology of Research in Immunology
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
12ms
Platinum Talen-Mediated Knock-in of Single-Stranded DNA Templates Facilitates Manufacturing of Clinical-Scale Non-Virally Gene-Edited T Cells from Peripheral Blood (ASH 2023)
As a model TCR, we selected a 1G4 clone that reacts with NY-ESO-1-derived peptide in an HLA-A*02-restricted manner... We have successfully designed Platinum TALEN mRNA pairs targeting TRAC and TRBC which facilitate the production of genome-edited human primary T cells. We also developed an electroporation and expansion culture protocol that enables us to produce viable genome-edited 1G4-transduced T cells at a large cell dose equivalent to a clinical scale. Collectively, these results suggest that targeted orthotopic knock-in of antigen-specific TCR-encoding ssDNA into the TCR locus by the use of Platinum TALEN is a promising strategy that can be applied for the clinical manufacturing of therapeutic TCR-T cells.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CTAG1B (Cancer/testis antigen 1B) • IL2 (Interleukin 2)
|
HAVCR2 expression • HLA-A*02 • HLA-A2 positive • PD-1 positive
|
NY-ESO-1 combined with MPLA vaccine
1year
Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model (ASH 2023)
Primary T cells from two donors were transduced with lentivirus containing a NY-ESO-1 TCR as well as a genome-wide sgRNA library and subsequently CRISPR edited using Cas9-RNP electroporation...The template for the B Cell Maturation Antigen (BCMA)-specific CAR bb2121 was then delivered to the TRAC locus via CRISPR/Cas9-RNP and adeno-associated virus (AAV)...We found a significant advantage in tumor killing of CUL5 ablated T cells compared to control cells in this ex vivo setting, suggesting an improved functional persistence. In summary, our findings identify the CUL5 complex as a novel potential therapeutic target to improve T cell persistence and counteract T cell exhaustion in order to improve the efficacy of adaptive cell immunotherapies for the treatment of BCMA+ hematological malignancies.
CAR T-Cell Therapy • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CTAG1B (Cancer/testis antigen 1B) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
|
Abecma (idecabtagene vicleucel) • NY-ESO-1 combined with MPLA vaccine
over3years
[VIRTUAL] CRISPR-Mediated Genome Editing to Redirect T Cells against Non-Small Cell Lung Cancer (ASGCT 2021)
TCR-engineered T cells derived from HLA-A*0201-typed NSCLC patients co-cultured with patient-derived cancer cells expressing NY-ESO-1 and analysed by flow cytometry for their killing activity, demonstrated that TCR engineering enabled T cells to recognize and kill NSCLC cells. These data strongly encourage the application of CRISPR-mediated non-viral TCR editing to generate tumor-specific T cells able to kill NSCLC cells, contributing to the preclinical validation of adoptive T cell therapy with CRISPR-mediated engineered T cells for the treatment of lung cancer.
IO biomarker
|
CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
NY-ESO-1 combined with MPLA vaccine